

1 **Digital health app data reveals an effect of ovarian hormones on long COVID and myalgic**
2 **encephalomyelitis symptoms**

3

4 **Authors:** Abigail Goodship MRes¹, Rory Preston MSc², Dr. Joseph T Hicks PhD³, Harry Leeming
5 MEng², Christian Morgenstern MSci³, Dr. Victoria Male PhD¹

6

7 1. Department of Metabolism, Digestion and Reproduction, Imperial College London, Chelsea
8 and Westminster Campus, London SW10 9NH

9 2. Visible Health Inc., 251 Little Falls Dr., Wilmington DE, USA

10 3. MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health,
11 Imperial College London, London, W12 7TA, UK

12

13 **Corresponding author:** Dr. Victoria Male PhD¹

14 **Telephone:** 020 3315 800

15 **Email:** v.male@imperial.ac.uk

16

17 **Summary**

18 **Background**

19 Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) disproportionately
20 affect females, suggesting modulation by sex hormones. We sought to investigate whether symptom
21 severity is influenced by changes in sex hormones over the menstrual cycle, or by hormonal
22 contraception.

23 **Methods**

24 We carried out a retrospective analysis of menstrual and symptom data, prospectively collected via
25 the Visible app from individuals with long COVID, ME/CFS, or both, who had regular menstrual
26 cycles, between 7th September 2022 and 6th March 2024. Mixed-effects models were used to
27 examine associations between symptom severity, menstrual cycle phase and contraception type.

28 **Findings**

29 948 users were included; 100% of users were female and 92.6% identified as women. The most tracked
30 symptoms were fatigue (99.5% of users), brain fog (88.3%), headaches (85.1%) and muscle aches
31 (78.6%). All menstrual cycle phases showed a modest, but significant, improvement compared to the
32 menstrual phase, most markedly the early luteal (IRR = 0.963, 95% CI: 0.958–0.968), but also the
33 follicular (IRR = 0.985, 95% CI: 0.981–0.990) and late luteal phases (IRR = 0.980, 95% CI: 0.974–
34 0.985). Crashes (sudden and severe worsening of symptoms following exertion) were significantly more
35 frequent during menstruation than in other phases. Users of combined hormonal contraception (n=70)
36 had a statistically significant reduction in overall symptom score (OR = 0.827, 95% CI: 0.690–0.992)
37 and crash incidence (OR = 0.548, 95% CI: 0.350–0.856) compared to those not using contraception
38 (n=786).

39 **Interpretation**

40 Menstruation is associated with worsened symptoms in long COVID and ME/CFS. Users of combined
41 hormonal contraception report a lower symptom burden than non-users, suggesting a modulatory role
42 of ovarian hormones. These findings could empower menstruating people living with long COVID and
43 ME/CFS to anticipate cyclical changes in symptoms and plan their activities accordingly, and could
44 also inform their use of contraception.

45 **Funding**

46 UK Medical Research Council, NIHR, Community Jameel, the Eric and Wendy Schmidt Fund for
47 Strategic Innovation, Bill & Melinda Gates Foundation, Borne, Action Medical Research, and Genesis
48 Research Trust.

49

50 Introduction

51 Four years after the first identification of novel coronavirus SARS-CoV-2, the spread of coronavirus
52 disease 2019 (COVID-19) continues to profoundly impact people's lives. Whilst most SARS-CoV-2
53 infections resolve within 4 weeks, over 10% progress to a chronic multisystemic condition known as
54 'long COVID'.¹ The Winter COVID-19 Infection study, conducted between November 2023 and March
55 2024, estimated that 2 million people currently live with long COVID in the UK.² Of those who reported
56 having long COVID, 71.1% reported having long COVID for over a year, 51.3% over 2 years and 30.6%
57 over 3 years.² Long COVID symptoms are wide-ranging, but commonly include fatigue, brain fog,
58 shortness of breath, insomnia and post-exertional malaise,³ and can significantly reduce quality of life.⁴

59 A substantial fraction of long COVID cases also meet the diagnostic criteria for myalgic
60 encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS).⁵⁻⁸ Whilst not all cases of
61 ME/CFS have an identifiable infectious trigger, many are preceded by a viral infection such as glandular
62 fever,⁹ or Ross River virus.¹⁰ The prevalence of ME/CFS is estimated to be between 0.59% and 1.3%,¹¹⁻
63 ¹³ and around a quarter of people living with with ME/CFS are housebound.¹⁴ Despite the profound
64 impact ME/CFS can have on quality of life, research has been consistently underfunded.¹⁵ Given the
65 historic neglect of ME/CFS and the recent emergence of long COVID, as well as the complexity of both
66 diseases, many questions about their pathophysiology remain unanswered.

67 Long COVID and ME/CFS both affect approximately twice as many females as males^{16,17} and higher
68 oestrogen may be beneficial in females with acute COVID-19.^{18,19} Whilst the pathophysiology of long
69 COVID and ME/CFS are still unclear, a dysregulated immune response may play a role, with the
70 discovery of autoantibodies in long COVID patients supporting the suggestion that long COVID could
71 be an autoimmune disease.^{6,20} Sex hormones (oestrogen, progesterone and testosterone) modulate
72 sex differences in immune function²¹ and phases of the menstrual cycle correlate with symptoms of
73 chronic, and particularly autoimmune, conditions,²² summarised in **Figure 1**. Symptoms of rheumatoid
74 arthritis, inflammatory bowel disease, lupus, multiple sclerosis and asthma all worsen at or shortly
75 before menstruation.²² Hormonal contraception alters the cyclical fluctuations in ovarian hormones
76 across the menstrual cycle and has an association with altered disease susceptibility and severity,²²
77 with users experiencing improved symptoms of multiple sclerosis.²³

78 Cross-sectional surveys have suggested that long COVID symptoms may also vary with the
79 menstrual cycle,^{3,24} but these approaches can be affected by recruitment and recall bias. Many
80 individuals track both menstrual cycles and disease symptoms using apps, entering data in real-time
81 as part of their healthcare routine. Data collected in this way are less likely to be affected by
82 recruitment bias than other methods of data collection.²⁵ Visible is an app designed for people with
83 chronic health conditions (such as long COVID and ME/CFS) to track aspects of their health including
84 symptoms, biometric measurements and other factors such as menstruation.²⁶ In this study, we used
85 data from the Visible app to test two hypotheses: 1) Long COVID and ME/CFS symptoms are worse
86 during the menstrual and premenstrual phases, improving in the mid-luteal phase, and 2) stabilising
87 ovarian hormone levels with hormonal contraception is associated with improved symptoms.

88 **Research in context**

89
90 **Evidence before this study**

91 In acute COVID-19, there is evidence to suggest that oestrogen may have a protective effect. A
92 Swedish cohort study of post-menopausal women infected with SARS-CoV-2 (Sund *et al.*, 2022)
93 found that women with high oestrogen had a lower risk of death compared to controls and women
94 with low oestrogen had higher risk of death compared to controls. Furthermore, a population-based
95 matched cohort study of UK women found that users of the combined hormonal contraceptive pill
96 (n=295,689) had lower rates of COVID-19 and a reduction in hospital attendance (Costeira *et al.*,
97 2021). To our knowledge, the impact of the menstrual cycle on ME/CFS symptoms had yet to be
98 investigated prior to this study and research into long COVID and the menstrual cycle to date has
99 been limited. Arguably one of the most influential studies in the general field of long COVID is from
100 Davis *et al.* 2021 who reported the results of a large international patient-led survey. In addition to
101 characterising symptom prevalence, Davis *et al.*, found that a third of menstruating participants (n
102 =1792) reported relapses of their long COVID symptoms immediately before or during their period. In
103 a smaller UK survey (Newson *et al.*, 2021, n = 460), 62% of female respondents with long COVID
104 reported that their symptoms of long COVID were worse on the days before their period. However, the
105 participant demographics were not reported, so it is unclear whether this is a representative sample.

106 **Added value of this study**

107 This study is the first to describe changes to long COVID and ME/CFS symptoms across the
108 menstrual cycle, using prospectively collected app data. Symptoms tended to be worse during the
109 menstrual phase and less severe during the early luteal phase, in line with our hypothesis and with
110 previous findings. This study is also the first to investigate the effect of hormonal contraception on
111 symptoms of long COVID and ME/CFS. Use of combined hormonal contraception was associated
112 with significantly ameliorated symptoms and a reduced risk of crashes.

113
114 **Implications of all the available evidence**

115 The finding that long COVID and ME/CFS symptoms follow a cyclical pattern over the menstrual cycle
116 not only gives us new insights into the role of sex hormones in these diseases but could also
117 empower menstruating patients to schedule more strenuous activities during phases of the cycle
118 when they are likely to have milder symptoms, and be less vulnerable to crashes (sudden and severe
119 worsening of symptoms following exertion). The finding that combined hormonal contraceptives as
120 associated with reduced symptoms could also inform the use of contraception in people living with
121 long COVID and ME/CFS.

122

123 **Methods**

124 ***Data source and collection***

125 A retrospective analysis of symptom severity and menstrual cycle phase was conducted on
126 prospectively collected data from users of the Visible app.²⁶ On registration, users enter their birth year,
127 gender and whether they consider themselves to have long COVID, ME/CFS or another condition. After
128 consenting to participate, users were asked to complete a survey on their use of hormonal
129 contraception, pregnancy status, breastfeeding status, number of pregnancies, and number of births.
130 Each day, users were prompted to self-report their commonly experienced symptoms on a 4-point Likert
131 scale [None, Mild, Moderate, Severe] and whether they are currently experiencing a crash (**appendix,**
132 **p23**). The following definition was provided: "Crashes usually occur as a part of post-exertional
133 symptom exacerbation and affect your ability to carry out your usual activities. They normally last a few
134 days." Reports entered between 7th September 2022 to 8th March 2024 were collected.

135 ***Data cleaning and menstrual cycle phase coding***

136 All data cleaning and subsequent analysis was conducted in RStudio version 2024.12.0+467.²⁷ Users
137 who did not complete the survey questions, or who were breastfeeding, pregnant or outside the age
138 range 18-45 were excluded. Under-18s were not included due to the additional ethical approval that
139 would have needed to be obtained when analysing data from children; over 45s were excluded due to
140 an increased likelihood of being perimenopausal. Any users who did not have either long COVID or
141 ME/CFS, who did not track menstrual data or who did not report a single day where they were
142 menstruating were also excluded. A menstrual cycle was counted from the first day of one menstrual
143 period to the first day of the next. The first day of a period was assigned based on the International
144 Federation of Gynecology and Obstetrics (FIGO) definition of a normal period²⁸ where the day fulfilled
145 all the following criteria: users reports being on period; user did not report being on their period the
146 previous 5 days; the following day and the day after the user either reported being on their period or did
147 not make a report; user did not report being on their period 9 and 10 days after.

148 Menstrual cycles that contained >2 consecutive days of missing menstrual tracking data or were outside
149 of the normal length of a cycle (24-38 days, as defined by FIGO²⁸) were removed from the dataset.
150 Exclusion of users and cycles is summarised in **Figure 1C-D**. For all remaining cycles, any missing
151 menstrual tracking data was imputed ('on period' or 'not on period') so that menstrual cycle phases
152 could be assigned. Data was imputed from the previous day with data, with the following exception:
153 missing data on the 9th or 10th day of the cycle was imputed as 'not on period', assuming duration of
154 menses does not exceed the normal 8 days.²⁸ The period end date was assigned where the day fulfilled
155 all the following criteria: user assigned as being on their period; user assigned as being on their period
156 at least the previous 2 days; user assigned as not being on their period the following day.

157 After defining the last day of the period, a menstrual cycle phase was assigned to each day, according
158 to the decision tree outlined in **Figure 1E**. This follows the assumption that the follicular phase is
159 variable, and the luteal phase consistently accounts for the final 14 days of each cycle.²⁹ The luteal

160 phase was further divided into the early luteal (14-8 days before the first day of period (D1), late luteal
161 (7-3 days before D1) and premenstrual phase (2 days before D1).

162 Once menstrual cycle phases had been assigned to each day of all included cycles, any symptom and
163 sleep tracking associated with that day were integrated into the dataset. Retrospective symptom
164 reporting (symptom reported >2 days after date) was removed to reduce the risk of recall bias.

165 ***Descriptive statistics and statistical testing***

166 Overall study population characteristics are summarised in **Table 1**. For each user, for each date, the
167 scores of each tracked symptom (all on a scale of 0-4) were summed to give an overall symptom score
168 and provide a single, comprehensive measure of a user's overall health, reflecting the cumulative
169 burden of symptoms. Incorporating the total number of symptoms experienced in addition to severity of
170 symptoms is important, as for many individuals with long COVID, navigating the volume of symptoms
171 feels overwhelming and unmanageable.³⁰ Gravidity was assessed as a binary variable (nulligravid or
172 multigravid), and the Mann-Whitney U-Test was used to test the association between gravidity and
173 mean symptom score. Kruskal-Wallis tests were used to assess the association between mean
174 symptom score and disease type, contraception type, quarters post-joining and age category. Post-hoc
175 pairwise comparisons were conducted with Dunn's tests, and p-values were adjusted using the
176 Bonferroni method to control for Type 1 error. For menstrual cycle phase, the mean of all overall
177 symptom scores across all dates in each cycle phase was calculated for each individual. The Friedman
178 test was used to compare symptom score means across phases. Post-hoc pairwise comparisons were
179 performed using the Nemenyi test. For R package details see **appendix (p23)**. For all variables
180 described above, the mean of the mean overall symptom scores is presented as scatter plots in **Figure**
181 **2**, with pairwise significant comparisons shown on the plot ($p < 0.05$). The percentage of days classified
182 as a crash was calculated out of the total days with data and displayed as a scatter plot with mean +/-
183 standard error of the mean (SEM).

184

185 ***Mixed-effects modelling***

186 Two separate generalized linear mixed-effects models were used to evaluate the effect of relevant
187 variables on different outcomes: overall symptom score and crash occurrence. First, a negative binomial
188 regression mixed-effects model was used to investigate overall symptom score. Fixed effects included
189 menstrual phase, age category, disease type, contraception type, nulligravidity, and time since joining.
190 'Individual' was considered a random effect, which is recommended in menstrual cycle research³¹ to
191 reliably estimate between-person differences in within-person changes across the cycle.³¹⁻³³ Second,
192 to evaluate the effect of the same set of variables on crash occurrence, a logistic regression (binomial
193 family with a logit link) mixed-effects model was used. Fixed effects included menstrual phase, disease
194 type, contraception type, quarters post-joining, nulligravidity and age category. 'Individual' was
195 considered a random effect, to account for within-subject variability. Details of both models can be found
196 in **appendix (p24-25)**.

197 ***Ethics***

198 All app users were given the option to consent to the use of their anonymised data for this study by
199 checking a box in the "Research" section of the Visible app. Ethical approval for this study was obtained
200 from the Research Governance and Integrity Team (study number 277771) at Imperial College London.

201 ***Role of the funding source***

202 The funders of the study had no role in the study design, data collection, data analysis, data
203 interpretation, or writing of the report.

204




Figure 1: Overview of the study

(A) A schematic representation of the menstrual cycle illustrates relative changes in pituitary and ovarian hormones, follicle development, and endometrial lining. Correlated changes in disease severity and infections are shown in the top panel, red indicates disease symptoms worsen/susceptibility to infection increases and green indicates disease symptoms improve/response to infection improves. Created in Biorender.com.³⁴

(B) Screenshots from the Visible app illustrate how users track individual disease symptoms, menstruation and crashes. Data was collected from 7th September 2022 to 6th March 2024. (C) Flow diagram to illustrate the data cleaning process of users. Red boxes show exclusions of users, blue boxes show the number of users (n) after exclusions. (D) Flow diagram to illustrate the data cleaning process of cycles after (C). Yellow boxes show cycle exclusions, turquoise boxes show the number of cycles (n) after exclusions. (E) The decision tree for assigning menstrual cycle phase to each day.

261 **Results**

262 Of the 2678 users who consented for their data to be used in the study period (7th September 2022 –
263 6th March 2024), 948 remained after data cleaning (**Figure 1C-D, Table 1**). Just under half the cohort
264 identified as having long COVID (45·5%), around a third as having ME/CFS (34·7%) and a fifth
265 (19·8%) as having both long COVID and ME/CFS. Almost all users identified as women (92·6%) and
266 as not disabled (99·6%). The majority of users were not on hormonal contraception (82·9%), and the
267 remainder were split fairly evenly between oestrogen and progestin combined hormonal contraception
268 (combined pill (7·0%) or patch (0·4%), hereafter called "combined hormonal contraception") and
269 progestin-only contraceptives (intrauterine system (5·5%) or progestogen-only pill (2·3%) or
270 contraceptive implant (1·9%)). Around two-thirds of users had never been pregnant (65·1%) or given
271 birth (72·5%). The median user age was 37 (interquartile range = 10, distribution shown in **appendix**
272 **(p3)**). There were no significant differences between the characteristics of study participants in each of
273 the disease groups **appendix (p3)**.

Table 1. Demographics of study population


| Variable | Subgroups | Count (n) | Percentage (%) |
|-------------------------------|-------------------------|-----------|----------------|
| Disease type | Long COVID | 431 | 45·5 |
| | ME/CFS | 329 | 34·7 |
| | Long COVID and ME/CFS | 188 | 19·8 |
| Age category | <30 years old | 179 | 18·9 |
| | 30-39 years old | 400 | 42·2 |
| | ≥40 years old | 369 | 38·9 |
| Gender | Woman | 878 | 92·6 |
| | Non-binary | 61 | 6·4 |
| | Prefer not to say | 6 | 0·6 |
| | Prefer to self-describe | 3 | 0·3 |
| Disabled | No | 944 | 99·6 |
| | Yes | 4 | 0·4 |
| Contraception type | None | 786 | 82·9 |
| | Combined pill | 66 | 7·0 |
| | Intrauterine system | 52 | 5·5 |
| | Progestogen-only pill | 22 | 2·3 |
| | Contraceptive implant | 18 | 1·9 |
| | Patch | 4 | 0·4 |
| Number of times been pregnant | 0 | 617 | 65·1 |
| | 1 | 87 | 9·2 |
| | 2 | 132 | 13·9 |
| | 3 | 112 | 11·8 |
| Number of times given birth | 0 | 687 | 72·5 |
| | 1 | 71 | 7·5 |
| | 2 | 135 | 14·2 |
| | 3 | 55 | 5·8 |

All variables are displayed as count (n) and percentage (%) of the total users (N = 948)

274 To determine how overall disease severity changed over the cycle and with demographic
275 characteristics, we examined the daily sum of all symptom ratings, the 'symptom score', with higher
276 scores indicating higher severity. For each individual, we calculated the mean symptom score across
277 all relevant days. The mean symptom score was lowest in the early luteal phase, significantly higher
278 in the follicular ($p=0.0043$) and late luteal phase ($p=0.0037$) and still higher in the menstrual ($p=1.5e-$
279 08) and premenstrual phases ($p=4.6e-05$) (**Figure 2B**). Mean symptom scores were highest in users
280 with both long COVID and ME/CFS and were lowest in users with long COVID alone (**Figure 2C**).
281 Mean symptom scores from users with different contraception types, time since joining, gravidity and
282 age categories did not significantly differ in this initial analysis (**Figure 2D-G**), although there was a
283 near significant difference ($p=0.076$) between users of no hormonal contraception compared to
284 combined hormonal contraception ($p=0.076$) (**Figure 2D**).

285 On multivariable mixed-effects regression modelling, as symptom score was positively skewed and
286 over-dispersed (**Figure 2A**), we used negative binomial regression and incorporated random
287 intercepts for each user. The association between menstrual cycle phase and symptom score
288 remained significant adjusting for contraception type, disease type, age category, gravidity and time
289 since joining the app (**Table 2**). Symptom scores were significantly higher during menstruation than in
290 all other cycle phases. Compared to the menstrual phase, the early luteal phase showed the greatest
291 reduction in symptom scores (incidence rate ratio (IRR)=0.963, $p=5.77E-46$); the follicular and late
292 luteal phases also showed significant reductions (IRR=0.985, $p=6.49E-09$ and IRR=0.980, $p=4.96E-$
293 13 , respectively); and the smallest reduction was observed in the premenstrual phase (IRR=0.992,
294 $p=0.0425$). In the regression model, symptom scores were significantly lower in users of combined
295 hormonal contraception (IRR=0.872, $p=0.041$), in comparison to users not on hormonal
296 contraception. Users on progestin-only contraception also had lower symptom scores compared to
297 users not on hormonal contraception, but the difference was not significantly different (IRR=0.985,
298 $p=0.848$). In comparison to those with long COVID, users with ME/CFS had significantly higher
299 overall symptom scores (IRR=1.21, $p=0.000408$), and users with both long COVID and ME/CFS had
300 even higher overall symptom scores (IRR=1.52, $p=6.11E-11$). Compared to reports submitted in the
301 first three months since joining the app, symptom scores significantly increased over time, and by the
302 fifth quarter IRR = 1.06, $p=7.8E-49$. This was associated with an increase in the number of
303 symptoms tracked over time (**appendix, p4**). Age and gravidity did not show a significant association
304 with symptom scores.

305



306
307

308

309

310
311
312
313
314
315
316
317
318
319
320

Figure 2: The effects of menstrual phase, disease type, contraception type, time, gravidity and age on mean symptom severity

(A) Distribution of mean symptom scores is shown as a histogram, binwidth = 0.5. (B-G) Mean symptom score was calculated by first summing the scores of each tracked symptom (all on a scale of 0-4) and secondly taking the mean across all days for each individual. Scatter plots show mean symptom score split by menstrual phase (B), disease type (C), contraception type (D), quarters post-joining (E), gravidity (F) and age category (G). Mean symptom score is displayed as mean +/- SEM. The Friedman test plus Nemenyi pairwise comparisons was used to test the significance between mean symptom score and menstrual phase, due to the repeated measures nature of the data. The Mann-Whitney U-Test was used to test the significance between gravidity and mean symptom score,

321 due to the binary nature of the variable. Unpaired Kruskal-Wallis tests was used to test significance
 322 for all other variables, Dunn's test was used for post-hoc comparisons and p values were adjusted
 323 using the Bonferroni method. $P > 0.05$ are considered not significant, $P \leq 0.05$ are given 1 asterisk (*),
 324 $P \leq 0.01$ are given 2 asterisks (**), $P \leq 0.001$ are given 3 asterisks (***), $P \leq 0.0001$ are given 4
 325 asterisks (****). (H) Scatter plot showing mean percentage of days classified as a crash, displayed as
 326 mean +/- SEM.
 327

Table 2. The fitting result of negative binomial regression model (overall symptom score)

| Fixed effects | Incidence rate ratio | 95% confidence interval (CI) (lower) | 95% CI (upper) | P value |
|------------------------------------|----------------------|--------------------------------------|----------------|-----------|
| Menstrual phase | | | | |
| Menses | - | - | - | - |
| Follicular | 0.985 | 0.981 | 0.990 | 6.49E-09* |
| Early luteal | 0.963 | 0.958 | 0.968 | 5.77E-46* |
| Late luteal | 0.980 | 0.974 | 0.985 | 4.96E-13* |
| Premenstrual | 0.992 | 0.985 | 1.00 | 0.0425* |
| Hormonal contraception type | | | | |
| None | - | - | - | - |
| Oestrogen & progestin | 0.827 | 0.690 | 0.992 | 0.041* |
| Progestin only | 0.985 | 0.839 | 1.15 | 0.848 |
| Disease type | | | | |
| Long COVID only | - | - | - | - |
| ME/CFS only | 1.21 | 1.09 | 1.35 | 0.000408* |
| Long COVID and ME/CFS | 1.52 | 1.34 | 1.73 | 6.11E-11* |
| Age category | | | | |
| < 30 | - | - | - | - |
| 30-39 | 0.982 | 0.860 | 1.12 | 0.790 |
| >= 40 | 0.913 | 0.789 | 1.06 | 0.223 |
| Gravidity | | | | |
| Multigravida | - | - | - | - |
| Nulligravida | 0.911 | 0.815 | 1.02 | 0.0992 |
| Quarters post-joining | | | | |
| 1 | - | - | - | - |
| 2 | 1.01 | 1.00 | 1.01 | 0.00207* |
| 3 | 1.01 | 1.00 | 1.02 | 0.000786* |
| 4 | 1.04 | 1.03 | 1.05 | 1.13E-29* |
| 5 | 1.06 | 1.05 | 1.06 | 7.8E-49* |
| 6 | 1.05 | 1.03 | 1.07 | 4.32E-05* |

* P value <0.05

Random effect: Individual (intercept) Variance: 0.5421 Standard deviation: 0.7363

328

329

330 The most tracked symptoms across all users were fatigue (99·5%), brain fog (88·3%), headaches
331 (85·1%) and muscle aches (78·6%) (**appendix, p4**). These symptoms were frequently co-reported
332 with each other and with the following symptoms: dizziness, nausea, muscle weakness, joint pain,
333 shortness of breath, palpitations, light sensitivity, noise sensitivity and memory issues (**appendix, p5-**
334 **6**). Restricting the analysis to the first three cycles enabled us to conduct Pearson's chi-squared tests
335 as there were equal numbers of cycles for each user, and in this analysis, 25/36 individual symptoms
336 differed significantly between menstrual cycle phases (**appendix, p7-9**). However, this approach may
337 overlook long-term trends and variations in symptoms over time so we also built individual regression
338 models for each symptom (**appendix, p10-21**). In this analysis 32/36 symptoms showed a significant
339 association between symptom severity and menstrual cycle phase, with 22 of these being worse in
340 the menstrual phase and better in the luteal phase (**appendix, p10-21**).

341 Approximately 85% of those affected by long COVID experience episodic symptoms that can rapidly
342 fluctuate from periods of symptom stability to severe exacerbations, resulting in significant functional
343 declines.³ These periods of severe worsening symptoms are often called “crashes” by those living
344 with complex chronic illnesses,³⁵ who may choose, where possible, to avoid scheduling strenuous
345 activities at times when they are more vulnerable to a crash. The frequency of crashes was higher
346 during menses, compared to all other phases, particularly the early luteal phase ($p = 0\cdot0002680$)
347 (**appendix, p22**). The mean percentage of days with crash was highest in the menstrual phase and
348 decreased over the cycle, plateauing between the early luteal and premenstrual phases (**Figure 2H**).
349 Adjusting for contraception type, disease type, age category, gravidity and time since joining the app
350 using a mixed-effects logistic regression model, crashes remained less frequent in every phase
351 compared to menstruation (**Table 3**). The late luteal phase showed the greatest reduction in crashes
352 (odds ratio (OR)=0·888, $p=5\cdot87E-05$) compared to the menstrual phase. The follicular, early luteal
353 and premenstrual phase also showed significant reductions (OR=0·947, $p=0\cdot0367$ and OR=0·900,
354 $p=0\cdot000109$ and OR=0·919, $p=0\cdot0333$, respectively).

355 Crashes were significantly less frequent in users on combined hormonal contraception (OR=0·548,
356 $p=0\cdot0409$), compared to users not on hormonal contraception. Users on progestin-only contraception
357 also had fewer crashes compared to users not on hormonal contraception but this was not
358 significantly different (OR=0·864, $p=0\cdot446$). In comparison to those with long COVID, users with
359 ME/CFS had significantly more crashes (OR=1·47, $p=0\cdot00291$) and users with both long COVID and
360 ME/CFS had higher odds of crash (OR=1·85, $p=4\cdot4E-05$). Age and gravidity were not significantly
361 associated with crashes.

362

363

Table 3. The fitting result of binomial regression model (crashes)

| Fixed effects | Odds ratio (OR) | 95% CI (lower) | 95% CI (upper) | P value |
|------------------------------------|-----------------|----------------|----------------|-----------|
| Menstrual phase | | | | |
| Menses | - | - | - | - |
| Follicular | 0.947 | 0.900 | 0.997 | 0.0367* |
| Early luteal | 0.900 | 0.853 | 0.949 | 0.000109* |
| Late luteal | 0.888 | 0.838 | 0.941 | 5.87E-05* |
| Premenstrual | 0.919 | 0.851 | 0.993 | 0.0333* |
| Hormonal contraception type | | | | |
| None | - | - | - | - |
| Oestrogen & progestin | 0.548 | 0.350 | 0.856 | 0.00822* |
| Progestin only | 0.864 | 0.593 | 1.260 | 0.446 |
| Disease type | | | | |
| Long COVID only | - | - | - | - |
| ME/CFS only | 1.47 | 1.14 | 1.89 | 0.00291* |
| Long COVID and ME/CFS | 1.85 | 1.38 | 2.48 | 4.4E-05* |
| Age category | | | | |
| < 30 | - | - | - | - |
| 30-39 | 0.752 | 0.549 | 1.03 | 0.0761 |
| >= 40 | 0.799 | 0.564 | 1.13 | 0.209 |
| Gravidity | | | | |
| Multigravida | - | - | - | - |
| Nulligravida | 1.00 | 0.768 | 1.30 | 0.998 |
| Quarters post-joining | | | | |
| 1 | - | - | - | - |
| 2 | 0.943 | 0.894 | 0.994 | 0.0304* |
| 3 | 0.937 | 0.881 | 0.997 | 0.0396* |
| 4 | 1.10 | 1.02 | 1.18 | 0.00916* |
| 5 | 0.979 | 0.903 | 1.06 | 0.598 |
| 6 | 1.09 | 0.851 | 1.40 | 0.495 |

* P value <0.05

Random effect: Individual (intercept) Variance: 0.5414 Standard deviation: 0.7358

364
365

366 Discussion

367 This study is the first to describe changes to long COVID and ME/CFS symptoms across the
368 menstrual cycle, using prospectively collected app data. In line with previous reports, overall symptom
369 scores and crash incidence varied by disease, with the lowest scores reported in individuals with long
370 COVID, higher scores in individuals with ME/CFS and the highest scores in individuals with both.⁷ The
371 most tracked symptoms and clustering are broadly in line with Davis *et al.* 2021 who found that
372 fatigue and brain fog were the most frequent symptoms in long COVID patients after 6 months of the
373 study, alongside post-exertional malaise/crashes³.

374 When daily symptom ratings were summed to form an overall symptom score, there were small but
375 significant changes between phases: symptoms were most severe in the menstrual and premenstrual
376 phases and least severe in the early luteal phase. We saw a similar pattern with crash incidence, and
377 these findings are in line with our hypothesis and with previous findings^{3,17}. When disease type, age,
378 reproductive history and contraception type were adjusted for, the menstrual cycle phase still had a
379 small, but significant impact on symptom score and crashes. Use of combined hormonal
380 contraception was associated with significantly ameliorated symptoms and a reduced risk of crashes.
381 This warrants further investigation as combined hormonal contraception is generally considered safe,
382 cheap and is already widely available – making it a promising approach to ameliorate long COVID
383 and ME/CFS symptoms.

384 The major strength of this study is its use of data prospectively collected from a large cohort of users
385 of the Visible app. Users enter data in real time as part of their personal healthcare routines, reducing
386 recall and recruitment bias. The availability of a large volume of data enabled us to examine changes
387 over the menstrual cycle in granular detail, since sufficient user-days were assigned to even the
388 shortest phase (premenstrual) for statistical analysis. The comprehensive list of 36 symptoms tracked
389 allows a thorough investigation into the effect of menstrual cycle phase on long COVID and ME/CFS.
390 The use of 4-point Likert scales for symptom severity ensured consistency in data reporting and
391 analysis. This approach also allowed us to calculate an ‘overall symptom score’ as a single
392 comprehensive indicator of a user’s health on any given day. We also examined individual symptoms
393 and crashes to provide a more detailed picture of symptom severity.

394 The use of app data also carries some limitations. Our data is a convenience sample. Individuals with
395 limited access to technology or digital literacy are unlikely to be app users, and individuals who choose
396 to use the app and participate in the study might also have different characteristics or health behaviours
397 compared to those who do not, potentially limiting the applicability of the results. Importantly, our study
398 also relies on self-reported disease status, which may introduce inaccuracies into disease group
399 assignments, and daily symptoms, which may introduce biases such as over-reporting or under-
400 reporting of symptoms, and inaccuracies in tracking. Different users might also interpret and rate
401 symptoms differently. However, to address this issue, we included ‘individual’ as a random effect in the
402 model. The userbase of the app also means that there are no healthy controls, which prevents us from
403 determining whether changes in long COVID and ME/CFS symptoms are due to the ovarian hormones

404 affecting the disease, or whether the observed change in symptoms reflects normal variation in
405 wellbeing across the menstrual cycle. However, our finding that combined hormonal contraception is
406 associated with lower symptom scores, does support the hypothesis that ovarian hormones directly
407 affect disease symptoms.

408 While our model adjusts for several variables, there may still be unmeasured confounders. Within-
409 individual analysis means that the association between symptom severity and menstrual cycle phase
410 is likely to be robust to this, but this could certainly affect the relationship between contraceptive use
411 and symptoms. Furthermore, the demographic survey questions were completed when the user first
412 enrolled and were not updated over the study. Therefore, any changes in contraception use during the
413 study would not have been captured. To minimise the cognitive burden of participation on app users,
414 we designed the survey to be as short as possible, but this meant we did not collect information on
415 other geographic location, ethnicity, socioeconomic status, body-mass index, education or other health
416 conditions including gynaecological disorders. Nor were we able capture daily contraception
417 information, including emergency contraception use, or any other hormonal intake (e.g. testosterone or
418 hormone replacement therapy (HRT)).

419 The results presented here support the idea that menstrual cycle phase influences long COVID and
420 ME/CFS symptoms. Broadly, people living with long COVID or ME/CFS may notice that their symptoms
421 are worse during the perimenstrual period and better in the early luteal phase. The knowledge that they
422 are more likely to crash during menstruation could improve quality of life, by allowing them to schedule
423 strenuous activities, which might cause a crash and cannot be carried out during a crash, for other
424 phases of the menstrual cycle. Furthermore, the association between combined hormonal
425 contraceptives, lower symptom scores and fewer crashes points towards a role for ovarian hormones
426 in modulating symptoms and highlights the therapeutic potential of oestrogen-containing contraceptives
427 in long COVID and ME/CFS.

428

429 **Declarations**

430 **Funding** AG is funded by the UK Medical Research Council (MRC) [grant number MR/W00710X/1].
431 CM acknowledges funding from the MRC Centre for Global Infectious Disease Analysis
432 (MR/X020258/1), the NIHR (NIHR200908); a philanthropic donation from Community Jameel
433 supporting the work of the Jameel Institute; The Eric and Wendy Schmidt Fund (G-22-63345). JTH
434 acknowledges funding from the Bill & Melinda Gates Foundation (INV-005289). VM acknowledges
435 funding from Borne, Action Medical Research (GN2971), the UK Medical Research Council
436 (MR/X006875/1) and Genesis Research Trust. The funders of the study had no role in the study
437 design, data collection, data analysis, data interpretation, or writing of the report. For the purpose of
438 open access, the author has applied a 'Creative Commons Attribution' (CC BY) licence to any Author
439 Accepted Manuscript version arising from this submission.

440

441 **Availability of data and materials** While all data used in this analysis were anonymised, the
442 individual-level nature of the data used risks individuals being identified or being able to self-identify if
443 it is released publicly. However, the app data can be requested by bona fide researchers for specified
444 scientific purposes by emailing info@makevisible.com.

445

446 **Code availability**

447 https://github.com/AbiGoodship/effect_of_ovarian_hormones_on_long_COVID_and_ME_symptoms

448

449 **Competing interests.** During the course of the study HL was employed by, and RP was a paid
450 contractor for Visible Health Inc., the company that owns and operates the Visible app. Some of the
451 study participants had paid for access to certain Visible features, though not access to symptom
452 tracking or menstrual cycle tracking functionality which is free for all Visible app users. This was a
453 study across both the free and paid user base. All other authors declare no competing interests.

454

455 **Authors' Contributions** VM and CM conceptualised the study. RP and HL curated the data. JH, AG
456 and CM developed the methodology. AG formally analysed and visualised the data. CM and VM
457 supervised the study. AG wrote the original manuscript draft. All authors were responsible for the
458 methodology and review and editing of the manuscript. All authors discussed, edited, and approved
459 the final version of the manuscript. All authors had final responsibility for the decision to submit the
460 manuscript for publication.

461

462 References

- 463 1 Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and
464 recommendations. *Nat Rev Microbiol.* 2023; **21**. DOI:10.1038/s41579-022-00846-2.
- 465 2 Self-reported coronavirus (COVID-19) infections and associated symptoms, England and
466 Scotland - Office for National Statistics.
467 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/selfreportedcoronaviruscovid19infectionsandassociatedsymptomsenglandandscotland/november2023tomarch2024#long-covid> (accessed July 22, 2024).
- 468 3 Davis HE, Assaf GS, McCorkell L, *et al.* Characterizing long COVID in an international cohort:
469 7 months of symptoms and their impact. *EClinicalMedicine* 2021; **38**.
470 DOI:10.1016/j.eclinm.2021.101019.
- 471 4 Carlile O, Briggs A, Henderson AD, *et al.* Impact of long COVID on health-related quality-of-
472 life: an OpenSAFELY population cohort study using patient-reported outcome measures
473 (OpenPROMPT). *The Lancet Regional Health - Europe* 2024; **40**: 100908.
- 474 5 Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome
475 (ME/CFS)-A systemic review and comparison of clinical presentation and symptomatology.
476 *Medicina (Lithuania)* 2021; **57**. DOI:10.3390/medicina57050418.
- 477 6 Sukocheva OA, Maksoud R, Beeraka NM, *et al.* Analysis of post COVID-19 condition and its
478 overlap with myalgic encephalomyelitis/chronic fatigue syndrome. *J Adv Res.* 2022; **40**.
479 DOI:10.1016/j.jare.2021.11.013.
- 480 7 Haider S, Janowski AJ, Lesnak JB, *et al.* A comparison of pain, fatigue, and function between
481 post-COVID-19 condition, fibromyalgia, and chronic fatigue syndrome: a survey study. *Pain*
482 2023; **164**: 385–401.
- 483 8 Kedor C, Freitag H, Meyer-Arndt L, *et al.* A prospective observational study of post-COVID-19
484 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers
485 associated with symptom severity. *Nature Communications* 2022 13:1 2022; **13**: 1–13.
- 486 9 Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic Fatigue Syndrome After Infectious
487 Mononucleosis in Adolescents. *Pediatrics* 2009; **124**: 189–93.
- 488 10 Hickie I, Davenport T, Wakefield D, *et al.* Post-infective and chronic fatigue syndromes
489 precipitated by viral and non-viral pathogens: prospective cohort study. *BMJ* 2006; **333**: 575.
- 490 11 Valdez AR, Hancock EE, Adebayo S, *et al.* Estimating prevalence, demographics, and costs of
491 ME/CFS using large scale medical claims data and machine learning. *Front Pediatr* 2019; **6**:
492 433309.
- 493 12 Vahratian A, Lin J-MS, Bertolli J, Unger ER. Myalgic Encephalomyelitis/Chronic Fatigue
494 Syndrome in Adults: United States, 2021-2022. 2023; published online Dec 13.
495 DOI:10.15620/CDC:134504.
- 496 13 Samms GL, Ponting CP. Unequal access to diagnosis of myalgic encephalomyelitis in
497 England. *medRxiv* 2024; : 2024.01.31.24302070.
- 498 14 Pendergrast T, Brown A, Sunnquist M, *et al.* Housebound versus nonhousebound patients with
499 myalgic encephalomyelitis and chronic fatigue syndrome. *Chronic Illn* 2016; **12**: 292–307.
- 500 15 Smith K. Women's health research lacks funding — these charts show how. *Nature* 2023; **617**.
501 DOI:10.1038/d41586-023-01475-2.
- 502 16 Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of
503 the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *J Transl
504 Med* 2020; **18**. DOI:10.1186/S12967-020-02269-0.
- 505 17 Sigfrid L, Drake TM, Pauley E, *et al.* Long Covid in adults discharged from UK hospitals after
506 Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical
507 Characterisation Protocol. *The Lancet Regional Health - Europe* 2021; **8**.
508 DOI:10.1016/j.lanepe.2021.100186.
- 509 18 Sund M, Fonseca-Rodríguez O, Josefsson A, Welen K, Fors Connolly AM. Association
510 between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and
511 death due to COVID-19: A cohort study. *BMJ Open* 2022; **12**. DOI:10.1136/bmjopen-2021-
512 053032.
- 513 19 Costeira R, Lee KA, Murray B, *et al.* Estrogen and COVID-19 symptoms: Associations in
514 women from the COVID Symptom Study. *PLoS One* 2021; **16**.
515 DOI:10.1371/journal.pone.0257051.
- 516 20 Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long
517 COVID. *Nat Rev Immunol.* 2023; **23**. DOI:10.1038/s41577-023-00904-7.
- 518 21 Hoffmann JP, Liu JA, Seddu K, Klein SL. Sex hormone signaling and regulation of immune
519 function. *Immunity.* 2023; **56**. DOI:10.1016/j.immuni.2023.10.008.
- 520
521

- 522 22 Alvergne A, Höggqvist Tabor V. Is Female Health Cyclical? Evolutionary Perspectives on
523 Menstruation. *Trends Ecol Evol.* 2018; **33**. DOI:10.1016/j.tree.2018.03.006.
- 524 23 Kempe P, Hammar M, Brynhildsen J. Symptoms of multiple sclerosis during use of combined
525 hormonal contraception. *European Journal of Obstetrics and Gynecology and Reproductive*
526 *Biology* 2015; **193**. DOI:10.1016/j.ejogrb.2015.06.030.
- 527 24 Newson L, Lewis R, O'Hara M. Long Covid and menopause - the important role of hormones
528 in Long Covid must be considered. *Maturitas* 2021; **152**. DOI:10.1016/j.maturitas.2021.08.026.
- 529 25 Milne-Ives M, Van Velthoven MH, Meinert E. Mobile apps for real-world evidence in health
530 care. *Journal of the American Medical Informatics Association.* 2020; **27**.
531 DOI:10.1093/jamia/ocaa036.
- 532 26 Visible - Activity tracking for Long Covid and ME/CFS. <https://www.makevisible.com/>
533 (accessed Aug 2, 2024).
- 534 27 Posit team. RStudio: Integrated Development Environment for R. 2024.
- 535 28 Munro MG, Critchley HOD, Fraser IS, *et al.* The two FIGO systems for normal and abnormal
536 uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the
537 reproductive years: 2018 revisions. *International Journal of Gynecology and Obstetrics* 2018;
538 **143**. DOI:10.1002/ijgo.12666.
- 539 29 Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. 2000.
- 540 30 Wurz A, Culos-Reed SN, Franklin K, DeMars J, Wrightson JG, Twomey R. 'I feel like my body
541 is broken': exploring the experiences of people living with long COVID. *Quality of Life*
542 *Research* 2022; **31**. DOI:10.1007/s11136-022-03176-1.
- 543 31 Schmalenberger KM, Tauseef HA, Barone JC, *et al.* How to study the menstrual cycle:
544 Practical tools and recommendations. *Psychoneuroendocrinology.* 2021; **123**.
545 DOI:10.1016/j.psyneuen.2020.104895.
- 546 32 Wei SM, Schiller CE, Schmidt PJ, Rubinow DR. The role of ovarian steroids in affective
547 disorders. *Curr Opin Behav Sci.* 2018; **23**. DOI:10.1016/j.cobeha.2018.04.013.
- 548 33 Gehlert S, Song IH, Chang CH, Hartlage SA. The prevalence of premenstrual dysphoric
549 disorder in a randomly selected group of urban and rural women. *Psychol Med* 2009; **39**.
550 DOI:10.1017/S003329170800322X.
- 551 34 Scientific Image and Illustration Software | BioRender. <https://www.biorender.com/> (accessed
552 Aug 8, 2024).
- 553 35 O'Brien KK, Brown DA, McDuff K, *et al.* Conceptualising the episodic nature of disability
554 among adults living with Long COVID: a qualitative study. *BMJ Glob Health* 2023; **8**.
555 DOI:10.1136/BMJGH-2022-011276.
- 556